Literature DB >> 15950101

Role of MRI for the diagnosis and prognosis of multiple myeloma.

Andrea Baur-Melnyk1, Sonja Buhmann, H R Dürr, Maximilian Reiser.   

Abstract

For the correct staging of patients with multiple myeloma sensitive detection is mandatory in order to estimate prognosis and to decide for adequate therapy. Magnetic resonance imaging (MRI) is superior to radiography for both, focal and diffuse involvement. Five different infiltration patterns can be differentiated: (1) normal appearance of bone marrow despite minor microscopic plasma cell infiltration, (2) focal involvement, (3) homogeneous diffuse infiltration, (4) combined diffuse and focal infiltration, (5) "salt-and-pepper"-pattern with inhomogeneous bone marrow with interposition of fat islands. For the fast and complete assessment of all patterns a combination of a T1-weighted spin echo sequence and a fat suppression technique should be employed. The focal involvement is clearly demonstrated as areas of high signal intensity on, e.g. STIR images. Diffuse involvement is best detected on unenhanced T1-weighted SE sequences and it manifests as homogeneous signal reduction. It can be quantified objectively by calculation of the percentage of signal intensity increase after contrast material injection. With parallel imaging and special coil devices, such as total imaging matrix (Siemens systems, Avanto) a "screening" of the whole red bone marrow as for myeloma infiltration is possible within a reasonable time. Patients without bone marrow infiltration have a significantly longer survival than patients with bone marrow infiltration in MRI at the time of diagnosis. However, even in stage I disease (Durie and Salmon) and negative X-ray films bone marrow infiltration in MRI may be detected in 29-50% of patients. Those patients typically show an earlier disease progression. Recently, MRI has been implemented in the clinical staging of patients with multiple myeloma. MRI may also monitor response to therapy. Signs of good response in cases with focal involvement are: reduction of signal intensity on T2-weighted spin echo images, lack or rim-like enhancement after contrast material injection or even a normalisation of bone marrow signal. In case of diffuse involvement a partly patchy reconversion to fatty marrow can be seen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950101     DOI: 10.1016/j.ejrad.2005.01.017

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  42 in total

1.  Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study.

Authors:  Giuseppe Lucio Cascini; Carmela Falcone; Domenico Console; Antonino Restuccia; Marco Rossi; Antonello Parlati; Oscar Tamburrini
Journal:  Radiol Med       Date:  2013-06-26       Impact factor: 3.469

Review 2.  The evolving role of MRI in oncohaematological disorders.

Authors:  O Tamburrini; M A Cova; D Console; P Martingano
Journal:  Radiol Med       Date:  2007-07-24       Impact factor: 3.469

3.  Dual-energy CT of the bone marrow in multiple myeloma: diagnostic accuracy for quantitative differentiation of infiltration patterns.

Authors:  Aleksander Kosmala; Andreas Max Weng; Bernhard Krauss; Stefan Knop; Thorsten Alexander Bley; Bernhard Petritsch
Journal:  Eur Radiol       Date:  2018-06-07       Impact factor: 5.315

4.  (11)C-acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment.

Authors:  Chieh Lin; Chi-Lai Ho; Shu-Hang Ng; Po-Nan Wang; Yenlin Huang; Yu-Chun Lin; Tzung-Chih Tang; Shu-Fan Tsai; Alain Rahmouni; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-16       Impact factor: 9.236

Review 5.  Minimal residual disease testing after stem cell transplantation for multiple myeloma.

Authors:  A M Sherrod; P Hari; C A Mosse; R C Walker; R F Cornell
Journal:  Bone Marrow Transplant       Date:  2015-07-20       Impact factor: 5.483

Review 6.  Imaging of multiple myeloma: Current concepts.

Authors:  Thorsten Derlin; Peter Bannas
Journal:  World J Orthop       Date:  2014-07-18

Review 7.  PET/CT and MR imaging in myeloma.

Authors:  Michael E Mulligan; Ashraf Z Badros
Journal:  Skeletal Radiol       Date:  2006-08-17       Impact factor: 2.199

8.  Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation.

Authors:  Thorsten Derlin; Kersten Peldschus; Silvia Münster; Peter Bannas; Jochen Herrmann; Thomas Stübig; Christian R Habermann; Gerhard Adam; Nicolaus Kröger; Christoph Weber
Journal:  Eur Radiol       Date:  2012-07-29       Impact factor: 5.315

Review 9.  Multiple myeloma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2010-02-11       Impact factor: 3.909

Review 10.  Whole body MRI and PET/CT in haematological malignancies.

Authors:  Chieh Lin; Alain Luciani; Emmanuel Itti; Corinne Haioun; Alain Rahmouni
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.